SP 1

NanoString Platforms

Translating diagnostic signatures

Lymphoma is a very heterogeneous disease. Today we know that each lymphoma is as individual as the patient who suffers from it. From our previous work, we can now use gene expression signatures to distinguish sub-entities and to choose the optimal therapy. However, this analysis is demanding, expensive and only available at large clinical centres. In this project, we will make existing and new signatures applicable for routine pathological diagnosis. For this, we use a new diagnostic platform (nCounter® Analysis System), which allows cheaper, faster and easier investigation of the gene expression of a lymphoma and the use of FFPE (formalin-fixed paraffin-embedded) samples. This platform was not developed by us. Our contribution is to translate old signatures to the new platform, as well as to develop new, more highly resolved signatures.

A translated gene expression signature to distinguish Burkitt lymphomas (bright red), from diffuse large B-cell lymphomas (DLBCL, bright blue). The bright green cases are intermediate between the two main types. This diagnosis has direct consequence to treatment choice and is often hard to make without gene expression analysis.